Background-Associations of pathophysiological calf muscle characteristics with functional decline in people with lower extremity peripheral arterial disease are unknown. Methods and Results-Three hundred seventy participants with peripheral arterial disease underwent baseline measurement of calf muscle area, density, and percent fat with the use of computed tomography. Participants were followed up annually for 2 years. The outcome of mobility loss was defined as becoming unable to walk 1/4 mile or walk up and down 1 flight of stairs without assistance among those without baseline mobility limitations. Additional outcomes were Ն20% decline in 6-minute walk distance and becoming unable to walk for 6 minutes continuously among participants who walked continuously for 6 minutes at baseline. With adjustment for age, sex, race, body mass index, the ankle-brachial index, smoking, physical activity, relevant medications, and comorbidities, lower calf muscle density (P for trend Ͻ0.001) and lower calf muscle area (P for trendϭ0.039) were each associated with increased mobility loss rates. Compared with participants in the highest baseline tertiles, participants in the lowest tertile of calf muscle percent fat had a hazard ratio of 0.18 for incident mobility loss (95% confidence interval, 0.06 to 0.55; Pϭ0.003), and participants in the lowest tertile of muscle density had a 3.50 hazard ratio for incident mobility loss (95% confidence interval, 1.28 to 9.57; Pϭ0.015). No significant associations of calf muscle characteristics with 6-minute walk outcomes were observed. Conclusions-Our findings suggest that interventions to prevent mobility loss in peripheral arterial disease should focus on reversing pathophysiological findings in calf muscle.
C hronic lower extremity arterial ischemia is associated with adverse calf muscle characteristics. Histopathological data demonstrate that lower extremity ischemia is associated with apoptosis, type II muscle fiber atrophy, and proliferation of connective tissue in the gastrocnemius muscle. [1] [2] [3] Computed tomographic (CT) imaging demonstrates that lower extremity ischemia is associated with smaller calf muscle area and increased calf muscle percent fat compared with absence of ischemia. 4 
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Men and women with peripheral arterial disease (PAD) have greater functional impairment and faster rates of functional decline than persons without PAD. 4, 5 However, associations of ischemia-related pathophysiological calf muscle characteristics and decline in lower extremity functional performance are unknown. If pathophysiological calf muscle characteristics are associated with more rapid functional decline in PAD, then reversal of these adverse calf muscle characteristics may be important for preserving functional performance in PAD.
This study identified associations of CT-measured calf muscle characteristics with mobility loss and decline in 6-minute walk performance among men and women with PAD participating in the Walking and Leg Circulation Study (WALCS) II. 6 We hypothesized that lower calf muscle density, greater calf muscle percent fat, and smaller calf muscle area would be associated with a higher incidence of mobility loss and faster functional decline compared with more favorable calf muscle characteristics in PAD. To determine whether these associations were specific to PAD, we also studied associations of these calf muscle characteristics with functional decline in persons without PAD.
Methods

Study Overview
The institutional review boards of Northwestern University and Catholic Health Partners Hospital approved the protocol. Participants gave written informed consent.
Participants were part of the WALCS II cohort, a prospective, observational study designed to identify mechanisms of functional decline in PAD. 6, 7 Participants underwent baseline measures and returned annually for follow-up. Participants unable to return for follow-up were interviewed by telephone for the mobility outcome measure.
Participant Identification
PAD participants were aged Ն59 years and were identified from among consecutive patients diagnosed with PAD in Chicago-area noninvasive vascular laboratories. 6, 7 Approximately half of non-PAD participants were identified consecutively from patients with normal lower extremity arterial studies in the same vascular laboratories. The remainder was identified from consecutive patients in a general medicine practice at Northwestern. A small number of PAD participants were identified from among consecutive patients in general internal medicine practice with a low ankle-brachial index (ABI) at their study visit. PAD was defined as ABI Ͻ0.90. [1] [2] [3] [4] Absence of PAD was defined as ABI Ն0.90 and Յ1.30. 6, 7 Participation rates and exclusion criteria for the WALCS II cohort have been described. 6, 7 Patients with dementia were excluded because of their inability to answer questions accurately. Nursing home residents, wheelchair-bound patients, and patients with foot or leg amputations were excluded because they have severely impaired functioning. Non-English-speaking patients were excluded because investigators were not fluent in non-English languages. Patients with recent major surgery were excluded.
ABI Measurement
After participants rested for 5 minutes in the supine position, a hand-held Doppler probe (Nicolet Vascular Pocket Dop II; Nicolet Biomedical Inc, Golden, Colo) was used to obtain systolic pressures in the right and left brachial, dorsalis pedis, and posterior tibial arteries. 4 -7 Each pressure was measured twice. The ABI was calculated by dividing the mean of the dorsalis pedis and posterior tibial pressures in each leg by the mean of the 4 brachial pressures. 4 -7 Zero values for the dorsalis pedis and posterior tibial pulses were excluded. Average brachial pressures in the arm with highest pressure were used when 1 brachial pressure was higher than the opposite brachial pressure in both measurement sets and the 2 brachial pressures differed by Ն10 mm Hg in at least 1 measurement set because subclavian stenosis was possible in these participants. 8 The lowest leg ABI was used in analyses.
Measuring Calf Skeletal Muscle Characteristics
With the use of a CT scanner (LightSpeed, General Electric Medical Systems, Waukesha, Wis), 2.5-mm cross-sectional images of the calves were obtained at 66.7% of the distance from the distal to the proximal tibia 6 (Figure) . Images were analyzed with the use of BonAlyse (BonAlyse Oy, Jyvaskyla, Finland), a software for processing CT images that identifies muscle tissue, fat, and bone. 6 The muscle outline was traced manually, excluding subcutaneous fat and bone. When muscle area is quantified, the BonAlyse software quantifies voxels within a range corresponding to muscle density (9 to 271 mg/cm 3 ) and excludes voxels corresponding to fat density (Ϫ270 to 8 mg/cm 3 ). Intramuscular fat is quantified by summing voxels corresponding to fat within muscle tissue. Cadaver studies demonstrate that these methods provide an estimate of muscle area that is highly correlated with direct anatomic measures. 9 Because larger individuals require greater muscle mass to support their frame, muscle area was adjusted for the square of individual tibia length. Muscle density measures the quantity of muscle per volume within the voxel range corresponding to muscle (9 to 271 mg/cm 3 ) and is a measure of muscle quality.
Functional Outcomes
Outcome measures were mobility loss, becoming unable to walk for 6 minutes continuously without stopping, and a decline in 6-minute walk performance of Ն20%. 10 These outcomes were assessed annually and were selected because they represent discrete end points and avoid a "floor" effect that may occur, for example, when a participant becomes unable to walk and cannot further deteriorate in functional performance.
Six-Minute Walk
The 6-minute walk was administered at baseline and at each annual follow-up visit. Following a standardized protocol, 11 participants walk up and down a 100-foot hallway for 6 minutes after instructions to cover as much distance as possible. The test administrator records whether the participant stopped during the 6-minute walk. Participants who stopped at baseline were excluded from analyses for the outcome of becoming unable to walk for 6 minutes continuously.
Mobility Measures
A critical factor in an older person's ability to function independently in the community is mobility, defined as the ability to walk or climb stairs without assistance. 12 Older people who lose mobility have higher morbidity and mortality and experience a poorer quality of life. 12, 13 At baseline and at each follow-up visit, participants were asked to indicate whether they could walk 1/4 mile and whether they could climb up and down 1 flight of stairs (1) on their own, (2) with assistance, or (3) not at all. 10, 12, 13 Mobility loss was defined as becoming unable to walk up and down 1 flight of stairs or walk 1/4 mile without assistance among those without mobility limitations at baseline. 10, 12, 13 
Comorbidities
Comorbidities assessed were diabetes mellitus, angina, myocardial infarction, heart failure, cancer, chronic lung disease, lower extremity arthritis, spinal disk disease, and stroke. Disease-specific algorithms that combine data from patient report, medical record review, medications, laboratory values, and a questionnaire completed by the participant's primary care physician were used to verify and document baseline comorbidities on the basis of criteria previously developed. 14 American College of Rheumatology criteria were used to document presence of knee and hip osteoarthritis. 15, 16 
Other Measures
Height and weight were measured at baseline. Body mass index (BMI) was calculated as weight (kilograms)/(height [meters]). 2 Cigarette smoking history was determined with patient report. At baseline, participants were asked to report the number of blocks they walked during the previous week with the use of a questionnaire validated previously. 17 Participants were asked to bring their medications to each study visit, and each medication was recorded. The principal investigator (M.M.M.) identified statin, pentoxifylline, and cilostazol use, blinded to other participant characteristics. At each follow-up visit, we used patient report, a primary care physician questionnaire, and medical record review to identify lower extremity revascularizations.
Statistical Analyses
Participants with and without PAD were categorized according to baseline tertiles of calf muscle area, calf muscle percent fat, and calf muscle density. Baseline characteristics of PAD participants across tertiles of each muscle characteristic were compared with general Cox regression analyses were used to compare rates of each functional outcome across tertiles of baseline calf muscle characteristic, separately for participants with and without PAD, with adjustment for confounders. A priori, we categorized participants into tertiles to ensure a reasonable sample size per category. For the outcome of mobility loss, participants with mobility limitations at baseline were excluded. For the outcome of becoming unable to walk for 6 minutes continuously, participants unable to walk for 6 minutes without stopping at baseline were excluded. Calf muscle characteristics were entered as continuous variables into the Cox regression analyses. Time to events was entered as "1" or "2" corresponding to the first or second annual follow-up visit. Participants who died or who underwent lower extremity revascularization during follow-up were censored at their last visit before these events. For PAD participants, 4 models were performed for each outcome. Model 1 adjusted for age, sex, and race. Model 2 adjusted for covariates in model 1 and ABI, BMI, smoking, and comorbidities (diabetes mellitus, angina, myocardial infarction, heart failure, cancer, lung disease, knee arthritis, hip arthritis, disk disease, and stroke). Model 3 adjusted for physical activity in addition to covariates in model 2. Model 4 adjusted for statin, pentoxifylline, and cilostazol use in addition to covariates in model 3. For non-PAD participants, only the first 3 models were performed. There were no significant deviations from the proportional hazards assumption for each outcome with the use of martingale residuals-based methods. 18 Statistical significance was defined as PϽ0.05. The study had 80% power to detect a hazard ratio of 0.45 (or 2.22) for mobility loss between the highest and lowest calf muscle tertiles. Analyses were performed with the use of SAS statistical software (version 9.2; SAS Institute Inc, Cary, NC).
Results
Four hundred thirty-nine participants in WALCS II had a baseline ABI Ͻ0.90 and underwent a CT scan. Of these, 370 (84%) met inclusion criteria for at least 1 outcome. Two hundred ninety-two participants in WALCS II had a baseline ABI of 0.90 to 1.30 and no history of lower extremity revascularization, consistent with PAD. Of these, 238 (90%) met inclusion criteria for at least 1 outcome.
Compared with those without PAD, PAD participants were older, had a lower BMI, and included higher proportions of men, current and former smokers, and individuals with diabetes mellitus and angina. Compared with those without PAD, PAD participants had lower calf muscle area, lower calf muscle density, and poorer functional performance (Table 1) . Table 2 shows characteristics of PAD participants by tertiles of each calf muscle characteristic. Lower calf muscle density was associated with older age, higher BMI, and higher prevalences of diabetes mellitus, pulmonary disease, and hip arthritis. Higher calf muscle percent fat was associated with older age, higher BMI, and higher prevalences of diabetes mellitus, pulmonary disease, and disk disease. Lower calf muscle area was associated with older age, lower ABI, higher BMI, fewer blocks walked during the prior week, and higher prevalences of men and blacks. Table 3 shows correlations between muscle characteristics among men and women with and without PAD, respectively. Table 4 shows associations of baseline muscle density with mobility loss at 2-year follow-up among 332 PAD participants with intact mobility at baseline. Lower calf muscle density was associated with increased mobility loss, with adjustment for age, sex, and race (model 1; Table 4 ; P for trend Ͻ0.001). Even after additional adjustment for ABI, BMI, comorbidities, and smoking, lower calf muscle density remained associated with an increased rate of mobility loss (model 2; Table 4 ; P for trend Յ0.001). Associations of lower calf muscle density with increased mobility loss remained statistically significant even after additional adjustment for physical activity (model 3; Table 4 ; P for trendϭ0.0001) and medication use (model 4; Table 4 ; P for trend Ͻ0.0001).
Calf Muscle Density and Functional Decline in PAD Participants
Among the 237 PAD participants able to walk for 6 minutes continuously at baseline, there were no significant associations of higher calf muscle density with becoming unable to walk for 6 minutes continuously at 2-year followup, with adjustment for confounders (Table 4) . Among all PAD participants, there were no significant associations of calf muscle density with Ն20% decline in 6-minute walk performance (data not shown). Table 5 shows associations of baseline calf muscle area with mobility loss at 2-year follow-up among 331 PAD participants with intact mobility at baseline. Lower calf muscle area was associated with increased mobility loss, with adjustment for age, sex, and race (model 1; Table 5 ; P for trendϭ0.005). Even after additional adjustment for ABI, BMI, comorbidities, and smoking, lower calf muscle area remained associated with increased mobility loss (model 2; Table 5 ; P for trendϭ0.004). This association remained statistically significant even after additional adjustment for physical activity (model 3; Table 5 ; P for trendϭ0.02) and even after additional adjustment for medication use (model 4; Table 5 ; P for trendϭ0.039). Among the 237 PAD participants able to walk for 6 minutes continuously at baseline, there were no significant associations of higher calf muscle area with becoming unable to walk for 6 minutes continuously at 2-year followup, with adjustment for confounders ( Table 5) . Among PAD participants, there were no significant associations of calf muscle area with a Ն20% decline in 6-minute walk performance (data not shown).
Calf Muscle Area and Functional Decline in PAD Participants
Calf Muscle Percent Fat and Functional Decline in PAD Participants
With adjustment for age, sex, and race, lower calf muscle percent fat was associated with lower rates of mobility loss at follow-up (P for trendϭ0.015) (Table 6 ; model 1). This association was no longer statistically significant after additional adjustment for ABI, BMI, comorbidities, and smoking (P for trendϭ0.074; Table 6 ; model 2). However, in a fully adjusted model, participants in the lowest baseline tertile of calf muscle percent fat had lower mobility loss compared with those in the highest baseline tertile of calf muscle fat (Pϭ0.003; Table 6 ; model 4). There were no associations of calf muscle percent fat with becoming unable to walk for 6 minutes continuously without stopping (Table 6 ) or with Ն20% decline in 6-minute walk performance (data not shown).
Participants Without PAD
Among participants without PAD, lower calf muscle density was associated significantly with increased mobility loss (P for trendϭ0.0003), and higher calf muscle percent fat was associated with increased mobility loss (P for trendϭ0.036), Data shown are hazard ratios (95% confidence intervals). Model 1 adjusts for age, sex, and race. Model 2 adjusts for variables in model 1 and ABI, BMI, smoking, and comorbidities. Model 3 adjusts for covariates in model 2 and physical activity level. Model 4 adjusts for covariates in model 3 and time-dependent use of statin, cilostazol, and pentoxifylline. The reference group is participants in the highest calf muscle density tertile at baseline. Analyses for mobility loss exclude participants with mobility limitation at baseline. Analyses for becoming unable to walk for 6 minutes continuously exclude participants who stopped during the 6-minute walk test at baseline. Because of sample size differences, tertiles are distinct for each outcome. *Pϭ0.005 relative to reference. †Pϭ0.010 relative to reference. ‡Pϭ0.015 relative to reference.
with adjustment for age, sex, race, BMI, comorbidities, and smoking. Only the association of lower calf muscle density with increased mobility loss remained statistically significant after additional adjustment for physical activity levels (P for trendϭ0.0005). Lower calf muscle area (P for trendϭ0.009) and higher calf muscle percent fat (P for trendϭ0.04) were each associated significantly with a Ն20% decline in 6-minute walk distance, with adjustment for age, sex, race, BMI, and comorbidities. After additional adjustment for physical activity, only calf muscle area (P for trendϭ0.012) remained associated significantly with a Ն20% decline in 6-minute walk performance. There were no significant associations of calf muscle density with functional decline in participants without PAD.
Discussion
Histopathological studies demonstrate that lower extremity ischemia is associated with calf muscle apoptosis, atrophy, loss of type II muscle fibers, and increased connective tissue. [1] [2] [3] Among participants included in the longitudinal analyses reported here, PAD was associated with significantly lower calf muscle area and lower calf muscle density but not with significantly higher calf muscle percent fat compared with absence of PAD. However, a prior study shows that PAD patients with significant ABI discrepancies between their right and left legs have lower calf muscle area and higher calf muscle percent fat in the leg with lowest ABI. 6 Together, these data indicate that lower extremity ischemia is associated with pathophysiological changes in calf muscle. [1] [2] [3] 6 The origin of pathophysiological calf muscle findings in PAD is likely multifactorial. Reduced physical activity, neuropathy, genetic factors, exercise activity, and comorbid diseases may all contribute to calf muscle pathophysiological findings in persons with PAD. To our knowledge, associations of adverse calf muscle characteristics with prospectively measured decline in functional performance have not been reported previously in men and women with PAD. Among PAD participants, we found that lower calf muscle density, lower calf muscle area, and higher calf percent fat were associated with increased mobility loss at 2-year followup. Associations of calf muscle density and calf muscle area with mobility loss remained statistically significant even after adjustment for multiple potential confounders, including physical activity and PAD-related medications. PAD participants in the most adverse baseline tertiles of calf muscle density and calf muscle percent fat had higher rates of mobility loss compared with those in the most favorable calf muscle tertiles at baseline. These findings demonstrate that calf muscle pathophysiological findings are associated independently with mobility loss in persons with PAD.
Among participants without PAD, lower calf muscle density was associated with increased mobility loss, and lower calf muscle area was associated with a Ն20% decline in 6-minute walk performance, even after adjustment for confounders including physical activity. Higher calf muscle percent fat was associated with increased mobility loss and with an increased risk of declining Ն20% in 6-minute walk distance, but these associations were no longer statistically significant after additional adjustment for physical activity. Our findings indicate that adverse calf muscle characteristics are associated with functional decline in persons both with and without PAD. However, because chronic lower extremity ischemia contributes to the muscle pathophysiological findings, the calf muscle pathology is potentially more clinically significant in PAD.
This study has limitations. First, the study is observational. Associations reported here cannot be construed as causal. Second, analyses for mobility loss were limited to participants without baseline mobility disability, and analyses for becoming unable to walk for 6 minutes continuously at follow-up were limited to those who walked for 6 minutes continuously at baseline. These characteristics and our exclusion criteria limit the generalizability of our findings. Third, muscle biopsy data were not available in our study cohort. Fourth, our study had limited statistical power to detect differences less than hazard ratios of 0.45 or 2.22 between highest versus lowest tertiles of calf muscle characteristics.
Mechanisms of functional impairment and decline in PAD are not well understood. For example, changes in the ABI over time are minimal even while patients with PAD experience significant functional decline. 5, 19 Our findings suggest that interventions to reverse mobility loss in PAD should focus on reversing adverse calf muscle characteristics. Although 1 small prior study demonstrated that leg strengthening increased muscle fiber density in PAD with intermittent claudication, 20 to our knowledge, no other studies have identified interventions that reverse adverse calf muscle characteristics in PAD.
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